$DNA

Ginkgo Bioworks (NYSE:DNA) integrated Araceli Biosciences' Endeavor imaging system into its Nebula lab, enhancing drug discovery capabilities. The system processes 1536-well plates in under four minutes and operates continuously, with software that analyzes and responds to data in real time. Both companies highlighted the integration's potential to scale biological data for AI-driven drug discovery.

Ginkgo Bioworks (NYSE:DNA) shares doubled after announcing a deal with Eli Lilly (NYSE:LLY) to use AI for drug discovery. Ginkgo's revenue fell to $20.2M in Q2, with an operating loss of $58.5M. Despite the rally, the stock is down 97% over five years, and past deals have not translated to strong financials.

Ginkgo Bioworks (DNA) has partnered with Lilly TuneLab to link AI models with lab data. Ginkgo will provide data generation services for small molecule and antibody testing, accelerating drug discovery. The collaboration aims to streamline AI-driven hypotheses with experimental results. DNA shares are up 2.86% at $7.18.

China’s Ministry of Commerce announced countermeasures against seven US entities, including Applied DNA Sciences (now BNB Plus Corp), Stratum Reservoir, Altana Technologies, Responsible Business Alliance, Verite Group, Human Rights in China, and Compliance Testing LLC, citing US sanctions over alleged forced labor in Xinjiang. The article links their roles to cotton traceability testing, AI supply-chain mapping, compliance services, and related government contracts.

Ginkgo Bioworks (NYSE:DNA) reported first-half 2026 cash burn of $93M, down 3% from $96M a year earlier. Management said Q1 cash burn included a $14M Google Cloud payment tied to an amended 2025 commitment that cut future minimums by over $100M and extended the term to six years. Ginkgo expanded its Nebula lab to 105 racks and raised $17M via an ATM.

Ginkgo Bioworks Holdings, Inc. (DNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland Ginkgo provides an update on its second quarter financial results and its continued efforts to scale Nebu

Ginkgo Bioworks Holdings, Inc. (DNA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. dna-20260611 0001830214 FALSE 0001830214 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________ FORM 8-K ______________________________________________________________ CURRENT RE

NPR reports that Ginkgo Bioworks in Boston is building an “autonomous lab” where AI and robots handle tasks such as pipetting, scheduling experiments, and designing work in areas including drug discovery, fertilizer microbes, and protein engineering. Founders Jason Kelly and Reshma Shetty say AI is increasingly generating hypotheses, including via an OpenAI collaboration. Stanford’s Drew Endy warns about biosecurity and loss of scientific know-how.

NPR reports that Ginkgo Bioworks in Boston is building an “autonomous lab” where AI directs robots to run experiments, including drug discovery, fertilizer microbes, and protein design. Founders Jason Kelly and Reshma Shetty say AI is moving from recipe-following to generating hypotheses, including a ChatGPT/OpenAI collaboration. Stanford’s Drew Endy warns about biosecurity and loss of scientific know-how.

NPR reports that Ginkgo Bioworks in Boston is building an “autonomous lab” where AI directs robots to run experiments, including drug discovery, microbes for fertilizer, and protein design. Founders say AI is shifting work from manual lab time to overnight robot execution, including AI-written lab notebook entries. Stanford’s Drew Endy warns about biosecurity and loss of scientific know-how.